Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neihulizumab - AltruBio

Next Previous
X
Search
Drug Profile

Neihulizumab - AltruBio

Alternative Names: AbGn-168; AbGn-168H; ALTB-168; Antibody-168

Latest Information Update: 28 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbGenomics Corporation
  • Developer AltruBio; Boehringer Ingelheim; Stanford University
  • Class Anti-inflammatories; Antihyperglycaemics; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; P-selectin ligand protein stimulants; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis; Ulcerative colitis
  • No development reported Graft-versus-host disease; Type 1 diabetes mellitus

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for phase-I development in Graft-versus-host-disease(In adolescents, Treatment-experienced, In adults) in USA (IV, Infusion)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Graft-versus-host-disease(Treatment-naive) in USA (IV, Infusion)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Plaque-psoriasis in Germany (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top